| MeSH term | MeSH ID | Detail |
|---|---|---|
| Asthenia | D001247 | 5 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Brain Diseases | D001927 | 27 associated lipids |
| Breast Neoplasms | D001943 | 24 associated lipids |
| Bronchial Spasm | D001986 | 18 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Hyperplasia | D006965 | 34 associated lipids |
| Hypopharyngeal Neoplasms | D007012 | 1 associated lipids |
| Leukemia | D007938 | 74 associated lipids |
| Leukemia P388 | D007941 | 43 associated lipids |
MAYTANSINE
MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.
Cross Reference
Introduction
To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with MAYTANSINE?
MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with MAYTANSINE
PubChem Associated disorders and diseases
What pathways are associated with MAYTANSINE
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with MAYTANSINE?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with MAYTANSINE?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with MAYTANSINE?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with MAYTANSINE?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with MAYTANSINE?
Xenograft Model
Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with MAYTANSINE
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Ponte JF et al. | Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody-Maytansinoid Conjugates. | 2016 | Bioconjug. Chem. | pmid:27174129 |
| Fan Y et al. | Effects of modulation of pentose-phosphate pathway on biosynthesis of ansamitocins in Actinosynnema pretiosum. | 2016 | J. Biotechnol. | pmid:27173582 |
| Jacot W et al. | Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases. | 2016 | Breast Cancer Res. Treat. | pmid:27167986 |
| Sandra K et al. | Multiple heart-cutting and comprehensive two-dimensional liquid chromatography hyphenated to mass spectrometry for the characterization of the antibody-drug conjugate ado-trastuzumab emtansine. | 2016 | J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. | pmid:27160547 |
| Tsuda M et al. | Abnormal Corneal Lesions Induced by Trastuzumab Emtansine: An Antibody-Drug Conjugate for Breast Cancer. | 2016 | Cornea | pmid:27149538 |
| Kwon Y et al. | Telangiectasia and Pulmonary Arterial Hypertension Following Treatment With Trastuzumab Emtansine: A Case Report. | 2016 | Chest | pmid:27055712 |
| Martin M et al. | Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study. | 2016 | Ann. Oncol. | pmid:27052654 |
| Coiffier B et al. | A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. | 2016 | Br. J. Haematol. | pmid:27010483 |
| Frenel JS et al. | [Trastuzumab emtansine in the systemic treatment of HER-2-positive breast cancer brain metastases]. | 2016 | Bull Cancer | pmid:26992855 |
| Lanshoeft C et al. | Analysis of small molecule antibody-drug conjugate catabolites in rat liver and tumor tissue by liquid extraction surface analysis micro-capillary liquid chromatography/tandem mass spectrometry. | 2016 | Rapid Commun. Mass Spectrom. | pmid:26969923 |
| Venkatesan P | Trastuzumab emtansine for HER2-positive breast cancer. | 2016 | Lancet Oncol. | pmid:27866859 |
| Sibaud V et al. | T-DM1 extravasation: first description. | 2016 | J Eur Acad Dermatol Venereol | pmid:25879278 |
| de Goeij BE and Lambert JM | New developments for antibody-drug conjugate-based therapeutic approaches. | 2016 | Curr. Opin. Immunol. | pmid:26963132 |
| Maass KF et al. | Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design. | 2016 | AAPS J | pmid:26912181 |
| Vankemmelbeke M and Durrant L | Third-generation antibody drug conjugates for cancer therapy--a balancing act. | 2016 | Ther Deliv | pmid:26893243 |
| Raja SM et al. | Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition. | 2016 | Oncotarget | pmid:26859680 |
| Kantarjian HM et al. | A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. | 2016 | Clin Lymphoma Myeloma Leuk | pmid:26775883 |
| Li JY et al. | A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy. | 2016 | Cancer Cell | pmid:26766593 |
| Catcott KC et al. | Microscale screening of antibody libraries as maytansinoid antibody-drug conjugates. | 2016 | MAbs | pmid:26752675 |
| Yan H et al. | Ado-Trastuzumab Emtansine Targets Hepatocytes Via Human Epidermal Growth Factor Receptor 2 to Induce Hepatotoxicity. | 2016 | Mol. Cancer Ther. | pmid:26712117 |
| Checkpoint Inhibitors Boost Power of Antibody-Drug Conjugate. | 2016 | Cancer Discov | pmid:26701087 | |
| T-DM1 Extends Survival in HER2+ Breast Cancer. | 2016 | Cancer Discov | pmid:26676162 | |
| Kan S et al. | Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells. | 2015 | BMC Cancer | pmid:26475267 |
| Montero JC et al. | Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling. | 2015 | Oncotarget | pmid:26336133 |
| Gébleux R et al. | Antibody Format and Drug Release Rate Determine the Therapeutic Activity of Noninternalizing Antibody-Drug Conjugates. | 2015 | Mol. Cancer Ther. | pmid:26294742 |
| Storz U | Antibody-drug conjugates: Intellectual property considerations. | 2015 | MAbs | pmid:26292154 |
| Nguyen M et al. | Preclinical Efficacy and Safety Assessment of an Antibody-Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma. | 2015 | Clin. Cancer Res. | pmid:26240273 |
| Chung YC et al. | Caveolin-1 Dependent Endocytosis Enhances the Chemosensitivity of HER-2 Positive Breast Cancer Cells to Trastuzumab Emtansine (T-DM1). | 2015 | PLoS ONE | pmid:26172389 |
| Beerli RR et al. | Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency. | 2015 | PLoS ONE | pmid:26132162 |
| van Geel R et al. | Chemoenzymatic Conjugation of Toxic Payloads to the Globally Conserved N-Glycan of Native mAbs Provides Homogeneous and Highly Efficacious Antibody-Drug Conjugates. | 2015 | Bioconjug. Chem. | pmid:26061183 |
| Miranda Romero P and MarÃn Gil R | Trastuzumab emtansine in locally advanced or metastatic HER2 positive breast cancer; GENESIS-SEFH drug evaluation report. | 2015 | Farm Hosp | pmid:26005893 |
| Esteva FJ et al. | What Can We Learn about Antibody-Drug Conjugates from the T-DM1 Experience? | 2015 | Am Soc Clin Oncol Educ Book | pmid:25993162 |
| Yabe N et al. | [A Case of Advanced Breast Cancer in Which Marked Improvement of Joint Pain Was Obtained with Stepwise Dose Reduction of Trastuzumab Emtansine (T-DM1)]. | 2015 | Gan To Kagaku Ryoho | pmid:26805183 |
| Müller P et al. | Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. | 2015 | Sci Transl Med | pmid:26606967 |
| Hong EE et al. | Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation. | 2015 | Mol. Pharm. | pmid:25856201 |
| Widdison W et al. | Metabolites of antibody-maytansinoid conjugates: characteristics and in vitro potencies. | 2015 | Mol. Pharm. | pmid:25826705 |
| Guerin M et al. | [Trastuzumab emtansine (Kadcyla(®)) approval in HER2-positive metastatic breast cancers]. | 2015 | Bull Cancer | pmid:25790739 |
| Nguyen-Ngoc T and Raymond E | Reinvention of chemotherapy: drug conjugates and nanoparticles. | 2015 | Curr Opin Oncol | pmid:25783982 |
| Mustacchi G et al. | HER2-positive metastatic breast cancer: a changing scenario. | 2015 | Crit. Rev. Oncol. Hematol. | pmid:25748080 |
| Salomon PL and Singh R | Sensitive ELISA Method for the Measurement of Catabolites of Antibody-Drug Conjugates (ADCs) in Target Cancer Cells. | 2015 | Mol. Pharm. | pmid:25738394 |
| Fishkin N | Maytansinoid-BODIPY Conjugates: Application to Microscale Determination of Drug Extinction Coefficients and for Quantification of Maytansinoid Analytes. | 2015 | Mol. Pharm. | pmid:25738231 |
| Goldmacher VS et al. | Statistics of the distribution of the abundance of molecules with various drug loads in maytansinoid antibody-drug conjugates. | 2015 | Mol. Pharm. | pmid:25635630 |
| Ahmed S et al. | HER2-directed therapy: current treatment options for HER2-positive breast cancer. | 2015 | Breast Cancer | pmid:25634227 |
| Foglietta J et al. | Letter to the editor concerning 'Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA'. | 2015 | Ann. Oncol. | pmid:25632067 |
| Wiggins B et al. | Characterization of cysteine-linked conjugation profiles of immunoglobulin G1 and immunoglobulin G2 antibody-drug conjugates. | 2015 | J Pharm Sci | pmid:25631158 |
| Lai KC et al. | Evaluation of Targets for Maytansinoid ADC Therapy Using a Novel Radiochemical Assay. | 2015 | Pharm. Res. | pmid:25630819 |
| Li T et al. | Improvement of ansamitocin P-3 production by Actinosynnema mirum with fructose as the sole carbon source. | 2015 | Appl. Biochem. Biotechnol. | pmid:25564203 |
| Baron JM et al. | Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. | 2015 | J Oncol Pharm Pract | pmid:24682654 |
| Singh JC and Lichtman SM | Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients. | 2015 | Drugs Aging | pmid:26645293 |
| Hamblett KJ et al. | SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm. | 2015 | Cancer Res. | pmid:26631267 |